Arbutus Biopharma (ABUS) Current Deferred Revenue (2010 - 2025)
Arbutus Biopharma (ABUS) posted Current Deferred Revenue of $6.8 million for Q1 2025, down 10.73% sequentially from $7.6 million in Q4 2024, and down 41.47% YoY from $11.5 million in Q1 2024.
Arbutus Biopharma (ABUS) Current Deferred Revenue (2010 - 2025) Analysis & Trends
Arbutus Biopharma has reported Current Deferred Revenue for 13 years, with the latest figure at $6.8 million in Q1 2025.
- Quarterly Current Deferred Revenue fell 41.47% year-over-year to $6.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $6.8 million (down 41.47% YoY) and the FY2024 annual result came in at $7.6 million, down 35.79% from the prior year.
- Current Deferred Revenue slipped to $6.8 million in Q1 2025 per ABUS's latest filing, from $7.6 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $23.3 million in Q1 2022 and troughed at $6.8 million in Q1 2025.
- A 4-year average of $13.4 million and a median of $12.1 million in 2023 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue decreased 9.7% in 2023, then plunged 41.47% in 2025.
- Over 4 years, Current Deferred Revenue stood at $16.5 million in 2022, then declined by 28.35% to $11.8 million in 2023, then slumped by 35.79% to $7.6 million in 2024, then dropped by 10.73% to $6.8 million in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.8 million, $7.6 million, and $10.9 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 6.76 Mn |
| Dec 31, 2024 | 7.57 Mn |
| Sep 30, 2024 | 10.91 Mn |
| Jun 30, 2024 | 11.03 Mn |
| Mar 31, 2024 | 11.55 Mn |
| Dec 31, 2023 | 11.79 Mn |
| Sep 30, 2023 | 12.11 Mn |
| Jun 30, 2023 | 15.33 Mn |
| Mar 31, 2023 | 15.06 Mn |
| Dec 31, 2022 | 16.46 Mn |
| Sep 30, 2022 | 14.88 Mn |
| Jun 30, 2022 | 16.97 Mn |
| Mar 31, 2022 | 23.26 Mn |
| Sep 30, 2018 | 649,000.00 |
| Jun 30, 2018 | 974,000.00 |
| Mar 31, 2018 | 1.72 Mn |
| Dec 31, 2017 | 2.74 Mn |
| Sep 30, 2017 | 15,000.00 |
| Jun 30, 2017 | 6.75 Mn |
| Mar 31, 2017 | 7.41 Mn |